Moreover, an upfront testing of all breast cancer cases would cut lead-times for molecular assay results and may also allow future implementation of prognostic or treatment predictive signatures in additional clinical subgroups, like TNBC and HER2-amplified cases, for which there are none in clinical use today. Here, ERBB2 is linked to breast cancer.